Company Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.
The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.
It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
| Country | Switzerland |
| Founded | 2013 |
| IPO Date | Oct 19, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 393 |
| CEO | Samarth Kulkarni |
Contact Details
Address: Baarerstrasse 14 Zug, 6300 Switzerland | |
| Phone | 41 41 561 32 77 |
| Website | crisprtx.com |
Stock Details
| Ticker Symbol | CRSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001674416 |
| CUSIP Number | H17182108 |
| ISIN Number | CH0334081137 |
| Employer ID | 47-3173478 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Samarth Kulkarni Ph.D. | Chief Executive Officer and Chairman |
| Dr. Raju Yashaswi Prasad Ph.D. | Chief Financial Officer |
| James R. Kasinger J.D. | General Counsel and Secretary |
| Dr. Naimish Patel C.M., M.D. | Chief Medical Officer |
| Shaun Foy CFA | Founder |
| Dr. Emmanuelle Marie Charpentier Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Craig C. Mello Ph.D. | Scientific Founder and Advisory Board Member |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder and Advisory Board Member |
| Dr. Daniel G. Anderson Ph.D. | Scientific Founder and Advisory Board Member |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2025 | 424B5 | Filing |
| May 19, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | SCHEDULE 13G/A | Filing |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 16, 2025 | ARS | Filing |
| Apr 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2025 | PRE 14A | Other preliminary proxy statements |